AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Roivant Sciences Ltd. Common Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG007STW2C7
35.44▲ 1.23 (3.60%)
As of 2026-10-09
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
34.21
Day's Range
34.15 – 35.59
52-Week Range
15.90 – 42.50
Volume
5.5M
Avg Volume
8.7M
Share Statistics
Shares Outstanding
Employees
750
Exchange
XNAS
Listed
2021-10-01
Share count as of July 31, 2026

Roivant Sciences Ltd. Common Shares (ROIV) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Roivant Sciences Ltd. Common Shares (ROIV)
What is Roivant Sciences Ltd. Common Shares's Market Cap?
Roivant Sciences Ltd. Common Shares's Market Cap is $25.6B, based on as-reported figures from SEC (XBRL) filings.
What is Roivant Sciences Ltd. Common Shares's Price / Sales?
Roivant Sciences Ltd. Common Shares's Price / Sales is 3398.7×, based on as-reported figures from SEC (XBRL) filings.
What is Roivant Sciences Ltd. Common Shares's Revenue (TTM)?
Roivant Sciences Ltd. Common Shares's Revenue (TTM) is $7.5M, based on as-reported figures from SEC (XBRL) filings.
What is Roivant Sciences Ltd. Common Shares's Net Income (TTM)?
Roivant Sciences Ltd. Common Shares's Net Income (TTM) is -$266.3M, based on as-reported figures from SEC (XBRL) filings.
What is Roivant Sciences Ltd. Common Shares's EBITDA?
Roivant Sciences Ltd. Common Shares's EBITDA is -$593.3M, based on as-reported figures from SEC (XBRL) filings.
What is Roivant Sciences Ltd. Common Shares's Diluted EPS (TTM)?
Roivant Sciences Ltd. Common Shares's Diluted EPS (TTM) is -0.37, based on as-reported figures from SEC (XBRL) filings.
What is Roivant Sciences Ltd. Common Shares's EBITDA Margin?
Roivant Sciences Ltd. Common Shares's EBITDA Margin is -7876.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ROIVAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-33.5%-66.7%-77.8%-64.9%
Operating expenses:
Cost of revenues
Research and development (includes $8,721 and $11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively)
General and administrative (includes $74,621 and $71,079 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively)
Total operating expenses
% of revenue25508.1%14187.1%17066.1%19592.9%
Gain on litigation settlement———
Loss from operations
% of revenue-25380.9%16477.8%-16966.1%-19492.9%
Change in fair value of investments
Change in fair value of liability instruments
Interest income
Other expense, net
Loss before income taxes
Income tax (benefit) expense
Net loss
% of revenue-20153.0%14116.8%-15692.9%-10569.0%
Net loss attributable to noncontrolling interests
Net loss attributable to Roivant Sciences Ltd.
% of revenue-13164.8%12023.6%-13301.2%-7225.9%
Net loss per common share - basic (in dollars per share)
Net loss per common share - diluted (in dollars per share)